Nicotine pouches are a newer class of smokeless products that don’t contain tobacco. Zyn became the first FDA-authorized ...

Mass General for Children's Dr. Scott Hadland discusses FDA approval of new nicotine pouch, Zyn.

Following an extensive scientific review, the U.S. Food and Drug Administration has authorized the marketing of 20 ZYN ...

The synthetic additive found in thousands of food products will now be phased out by 2027, but advocates say the agency's ...

The deal does not include a provision to raise the debt limit. After days of heated negotiations on Capitol Hill and eleventh-hour interference from President-elect Donald Trump and his ally Elon ...

Japan approves SIGA's TEPOXX, the first antiviral for orthopoxviruses, for smallpox, mpox, cowpox, and vaccine-related complications. Approval is based on 15 clinical trials and pivotal animal ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in the U.S., the agency has cleared an under-the-skin version of the ...

Bizengri received accelerated approval for NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma, showing ORRs of 33% and 40%, respectively, with varying DORs. Imfinzi significantly improved ...

The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that ...

IT IS SOMETIMES called the “Everest of rivers” owing to its extreme topography. One section of the Yarlung Tsangpo falls 2,000 metres over a stretch of 50km (31 miles). But what interests ...

2024 brought some major advancements in medicine. That includes the approval of "innovative" drugs like Tryvio for high blood pressure, Neffy for severe allergic reactions and Dupixent for chronic ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...